Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…
The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of 5.07% during the forecast period of 2017-2025. The market worth is expected to increase from $233 million in 2016 and reach $361.88 million by 2025. The ease in the availability of new and improved drugs and the growing geriatric population are currently driving the Asian Market.
The Asian market can be classified on the basis of drug type and prescription type. The drug type is further classified into naloxegol, lubiprostone, and methyl naltrexone bromide and some pipeline drugs such as naldemedine, alvimopan, dolcanatide and elobixibat. The prescription type is classified into generic and branded prescribed drugs and over the counter drugs. A large number of considerations while using opioids is a major challenge currently faced by the market.
Some of the major players in the market are
Daiichi Sankyo Co Ltd
Shionogi & Co., Ltd.
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Cosmo Pharmaceuticals Sa
Daewoong Pharmaceutical Co